Nano particle mediated delivery is a process in which Nanoparticles offer a stable means to achieve targeted drug delivery to various cells and tissues. The market is witnessing tremendous growth due to the rising aging population and increasing incidence of cardiovascular diseases and diseases associated with bones, ear, and others organ systems. The current trend in today’s market is to have such a medicated delivery system which is functional, targeted for specific disease and has high cytotoxicity (in case of cancer). With the rapid development of nanotechnology in the recent decade, novel DNA and RNA delivery systems for gene therapy have become available that can be used instead of viral vectors.

The forces which are responsible to drive the market are the advantages they have over viral vectors by decreasing immune response, and additionally offering flexibility in design, allowing them to be functionalized and targeted to specific sites in a biological system with low cytotoxicity For an instance if we talk about Diabetic retinopathy (DR) which is one of the leading cause of visual impairment and blindness world-wide. These non-viral vectors can be made of a variety of materials, including inorganic nanoparticles, carbon nanotubes, liposomes, protein and peptide-based nanoparticles, as well as nanoscale polymeric materials.

Genetic engineering of plants has also enhanced crop productivity in the face of climate change and a growing global population by dealing with desirable genetic traits to agricultural crops.

Conventional delivery methods are inefficient, damaging to tissue, or are only effective in a limited number of plant species. The driving force behind these Nanoparticles is that they are promising materials for biomolecule delivery and broad range applicability. With the advent of engineered nuclease biotechnologies, the potential of nanoparticles has an optimal platform to deliver biomolecules to plants for genetic engineering. Unfortunately, the restraints in this is intravitreal injections are associated with various complications such as intraocular bleeding, endophthalmitis, pain and discomfort resulting in poor patient compliance .

Key market players-Stryker Corporation (U.S.), 3M Company (U.S.), St. Jude Medical, Inc. (U.S.), Smith & Nephew, Inc. (U.K.), Affymetrix, Inc. (U.S.), PerkinElmer, Inc. (U.S.).

Key questions answered in this research report:

• •  At what pace is global nano particle mediated delivery market growing? What will be growth trend in future?
  •  What are the key drivers and restraints in the current market? What will be the impact of drivers and restraints in the future?
  •  What are the regional revenue and forecast breakdowns? Which are the major regional revenue pockets for growth in the Nano particle mediated delivery market?
  •  What are the various application areas and how they are poised to grow?

Market Segmentation

By Product Type Revenue Forecast till 2025

• Tablets
• Capsules
• Injections
• Others (Genetically modified plants etc.)

By Application Type Revenue Forecast till 2025

• Surgery
• Diagnostics
• Plant engineering
• Others

By End User Revenue Forecast till 2025

• Hospitals
• Clinics
• Others (Ascs and Diagnostic Laboratories)

By Geography

• North America

As a part of customization
o By Product type
o By Application
o By End User
o US
Canada
o Mexico

• Europe
o As a part of customization

o By Product type
o By Application
o By End User
o UK
o Germany
o Spain
o Rest of Europe

• Asia-Pacific
As a part of customization

o By Product type
o By Application
o By End User
o China
o Australia
o India
o Rest of APAC

• ROW (rest of the world)
o As a part of customization

By Product type
o By Application
o By End User
o Brazil
o South Africa
o GCC countries
o Rest of world (remaining countries of the LAMEA region)

Key market players

•  Stryker Corporation (U.S.)
•  3M Company (U.S.)
•  St. Jude Medical, Inc. (U.S.)
•  Smith & Nephew, Inc. (U.K.)
•  Affymetrix, Inc. (U.S.)
•  PerkinElmer, Inc. (U.S.).